drugset

drugset / Trial / NCT00042497

Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

NCT00042497 ↗

Phase 2 Suspended 60 enrolled Anosys

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma

Timeline

Start: 2002-07
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dexosomes	Unknown	—	—

Indications